CDK4 and cancer: By adding Faslodex, which degrades the ER, and Verzenio, a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor that targets the cell cycle, this treatment strategy goes beyond hormonal control to directly inhibit cancer cell proliferation.